FDA Clears Roche’s Wilserdly for ESR1-Mutated Breast Cancer
The oral drug, used with everolimus, cut the risk of disease progression or death by 62% in a Phase III trial’s ESR1-mutated group.
Makkler Newsroom · Nov 17, 01:36 AM · 1 min read
Market closed· · CHF · Data may be delayed
Avg. target CHF 396.62 (-4.2%)
Prices may be delayed and are for informational purposes only - not investment advice.
The oral drug, used with everolimus, cut the risk of disease progression or death by 62% in a Phase III trial’s ESR1-mutated group.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.